NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has regained compliance with a Nasdaq listing requirement regarding stockholders' equity.
The firm, which makes microRNA-based diagnostic products, said that it received notification from the Nasdaq Listing Qualifications Staff that it is now in compliance with a requirement that it have $2.5 million in stockholders' equity in order to remain listed on the Nasdaq Capital Market.
Last week, Rosetta said that it has regained compliance with another listing requirement — the $1 bid price for its stock. The firm recently effected a reverse one-for-15 reverse stock split, which was followed by a strong surge in its stock price.
It also announced last week that it had netted proceeds of about $6 million from a direct offering of 570,755 ordinary shares at $11.50 per share to certain investors.
In early Wednesday trade, shares of Rosetta were up 1 percent at $12.45.